FRIDAY, Aug. 10 (HealthDay News) -- Lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration to treat diabetic macular edema (DME), an eye condition that could threaten a diabetic person's sight, the agency said Friday in a news release.
The condition occurs when fluid leaks into the macula, the center of the eye's retina. This leads to macular swelling, causing blurred vision.
Diabetes is the leading cause of new cases of blindness among people aged 20 to 74, the FDA said, citing statistics from the U.S. Centers for Disease Control and Prevention.
Commonly reported side effects of Lucentis include bleeding of the eye's conjunctiva tissue, eye pain, floaters and increased pressure inside the eye.
Lucentis, marketed by San Francisco-based Genentech, was approved previously for wet age-related macular degeneration, and another form of macular edema.
The U.S. National Eye Institute has more about diabetic eye disease.
Copyright © 2012 HealthDay. All rights reserved.
|Previous: FDA Gives Nod to First Drug for Diabetic Eye Disease||Next: Mold Exposure in Infancy May Raise Asthma Risk|
Reader comments on this article are listed below. Review our comments policy.